The event will be moderated by Kirk Shepard, M.D., PDS Biotech’s Chief Medical Officer. A live question and answer session will follow the formal presentations. Date: Tuesday, June 17, 2025 Time: 12 p ...

A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a brain ...

Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung ...

The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements ...

When journalist Jon Gluck learned he had multiple myeloma, doctors told him he had 18 months to live. That was 20 years ago. ...

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, ...

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

aDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea bDivision of Hematology-Oncology, Department of ...

Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain ...